EUCTR2010-019980-13-NL进行中（未招募）不适用
Predictive value of baseline and stimulated serum IGF-I and IGFBP-3 during a dose-escalation IGF-I generation test with NutropinAq for the 1 year growth response to growth hormone (GH) therapy in short children with low IGF-I and a normal GH peak in a provocation test - IGF-I generation test
Ipsen Farmaceutica b.v.0 个研究点开始时间: 2011年7月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Prepubertal children aged 2.0-9.0 (females) or 2.0-10.0 (males) years, bone age <9 (females) or <10 (males) years, height SDS<-2.5 (for ethnically adequate references), peak GH after provocation >30 mU/L, IGF-I SDS < -2 (at least twice, one of which determined in UMCU), body mass index (BMI) SDS > -2
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Has a history of hypersensitivity to growth hormone or phenol (conservative added to GH in NutropinAq), or drugs with a similar chemical structure.
- •Was treated with any other Investigational Medicinal Product (IMP) within the last 30 days before study entry.
- •Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
- •Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject’s safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
- •Has a birth weight and/or length below -2 SDS for Swedish reference charts (2). Patients will not be excluded due to an unknown birth weight or length.
- •Has a known cause of short stature, or any significant concomitant disease that is likely to interfere with growth or with the study schedule/objectives, or is a known contraindication to GH treatment such as: chromosomal abnormalities (known syndromes associated with short stature, and skeletal dysplasias); growth failure due to high doses of glucocorticosteroids, hypothyroidism, chronic illnesses; malignancy, intra-cranial tumor; chronic disease such as insulin-dependent diabetes mellitus; chronic infectious disease; chronic renal insufficiency; chronic heart failure; chronic hepatic disease; celiac disease; chronic pulmonary disease; active rheumatic disease; psychosis; neurofibromatosis; McCune Albright syndrome; dysmorphic syndromes such as Russell-Silver syndrome, Leri-Weill syndrome, achondroplasia, etc; and emotional deprivation. Hypothyroidism adequately substituted with thyroid hormone replacement therapy is not an exclusion criterion. For girls, the karyotype, to eliminate a Turner syndrome, is mandatory. In case of a positive Rappold score (> 4) (3), a SHOX defect has to be excluded.
- •Has dysmorphic features suspect for chromosomal breakage syndromes.
- •Has known causes of decreased IGF-I (e.g. undernutrition).
- •Has an abnormal sitting height:height ratio SDS (<-2 or >+2), corrected for bone age, according to Dutch references (4).
- •Has any abnormality at laboratory screening according to the Dutch consensus protocol (see appendix 3).
- •Is likely to require treatment during the study with drugs that are not permitted by the study protocol (see appendix 4).
- •Has active neoplasia or suspected neoplasia.
- •The parents are investigator site personnel directly affiliated with the study, or are the immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as spouse, parent, child, or sibling, whether biological or legally adopted.
- •Is unable or unwilling to comply with the study visits or the test schedule required by the protocol.
- •Patients not affiliated to the health insurance system will not be allowed to participate in this trial.
研究者
相似试验
撤回
4 期
Predictive value of baseline and stimulated serum IGF-1 and IGFBP-3 during a dose-escalation IGF-1 generation test with NutropinAq for the 1 year growth response to growth hormone (GH) therapy in short children with low IGF-1 and a normal GH peak in a provocation testchildren with short stature of unknown cause10021112idiopathic short statureNL-OMON36350Ipsen Pharmaceuticals20
尚未招募
Unknown
To measure blood pre-operative serum N-terminal pro brain natriuretic peptide(NT-PROBNP) in detecting post-operative neurological deterioation in aneurysmal SAH.CTRI/2023/11/059850DEPARTMENT OF ANAESTHESIA AND INTENSIVE CARE
招募中
不适用
Study of Clinical outcomes and serum concentration of Meropenem in acute kidney injuryAcute kidney disease.Acute kidney failureIRCT20160412027346N5Shahid Beheshti University of Medical Sciences34
已完成
不适用
Evaluation of serum-biomarkers as a surrogate marker for florid MS lesions (contrast enhancement) in patients with multiple sclerosis.Multiple sclerosisG35DRKS00016029Klinikum der Johann Wolfgang Goethe-Universität Zentrum der Neurologie und Neurochirurgie102
已完成
3 期
A prospective study of the impact upon serum electrolyte and magnesium levels of using magnesium sulfate for bowel preparation for colonoscopy.ColonoscopyOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12608000160336Colocap Pharmaceuticals100